<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003782.pub3" GROUP_ID="SYMPT" ID="309202021816232513" MERGED_FROM="" MODIFIED="2015-10-12 11:33:03 +0100" MODIFIED_BY="Anna Hobson" REVIEW_NO="40" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2015-10-12 11:33:03 +0100" MODIFIED_BY="Anna Hobson">
<TITLE>Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy</TITLE>
<CONTACT>
<PERSON ID="15618" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Andrew</FIRST_NAME>
<MIDDLE_INITIALS>N</MIDDLE_INITIALS>
<LAST_NAME>Davies</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant in Palliative Medicine</POSITION>
<EMAIL_1>adavies12@nhs.net</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Palliative Medicine</DEPARTMENT>
<ORGANISATION>Royal Surrey County Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Guildford</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 208 661 3182</PHONE_1>
<PHONE_2>+44 117 928 3336</PHONE_2>
<FAX_1>+44 208 661 3185</FAX_1>
<FAX_2>+44 117 928 3865</FAX_2>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-10-12 11:32:38 +0100" MODIFIED_BY="Anna Hobson">
<PERSON ID="15618" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Andrew</FIRST_NAME>
<MIDDLE_INITIALS>N</MIDDLE_INITIALS>
<LAST_NAME>Davies</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant in Palliative Medicine</POSITION>
<EMAIL_1>adavies12@nhs.net</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Palliative Medicine</DEPARTMENT>
<ORGANISATION>Royal Surrey County Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Guildford</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 208 661 3182</PHONE_1>
<PHONE_2>+44 117 928 3336</PHONE_2>
<FAX_1>+44 208 661 3185</FAX_1>
<FAX_2>+44 117 928 3865</FAX_2>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1403101003277392553289740604565" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Jo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Thompson</LAST_NAME>
<SUFFIX/>
<POSITION>Clinical nurse specialist in supportive and palliative care</POSITION>
<EMAIL_1>jothompson3@nhs.net</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Palliative Medicine</DEPARTMENT>
<ORGANISATION>Royal Surrey County Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Guildford</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1483 571122 ext 4188 / blp 0941</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-10-12 11:32:38 +0100" MODIFIED_BY="Anna Hobson" NOTES="&lt;p&gt;AH: since RTOG 0537 has now been excluded, we suggest this review can be stabilised for 5 years. [We are now able to stabilise reviews if there is unlikely to be any new evidence, or if new evidence is unlikely to change the conclusions.] I have added the suggested date for 'Next stage expected' to 2020- let us know if you disagree.&lt;/p&gt;&lt;p&gt;Dates changed to 14 July 2015, which is when the searches were run.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-10-12 11:32:38 +0100" NOTES_MODIFIED_BY="Anna Hobson">
<UP_TO_DATE>
<DATE DAY="14" MONTH="7" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="14" MONTH="7" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="9" YEAR="2020"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-10-12 11:33:03 +0100" MODIFIED_BY="Anna Hobson">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2015-10-12 11:33:03 +0100" MODIFIED_BY="Anna Hobson">
<DATE DAY="12" MONTH="10" YEAR="2015"/>
<DESCRIPTION>
<P>This review will be assessed for further updating in 2020.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-10-12 11:32:51 +0100" MODIFIED_BY="Anna Hobson">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-10-12 11:32:49 +0100" MODIFIED_BY="Anna Hobson">
<DATE DAY="28" MONTH="7" YEAR="2015"/>
<DESCRIPTION>
<P>No new studies were identified that met the inclusion criteria for the review</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-10-12 11:32:51 +0100" MODIFIED_BY="Anna Hobson">
<DATE DAY="18" MONTH="4" YEAR="2014"/>
<DESCRIPTION>
<P>The review has been updated to reflect the current Cochrane guidelines for reporting reviews</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-04-17 15:25:36 +0100" MODIFIED_BY="Anna Hobson">
<DATE DAY="27" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-06-27 19:40:13 +0100" MODIFIED_BY="Jessica Thomas">
<DATE DAY="8" MONTH="2" YEAR="2011"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-02-08 10:48:59 +0000" MODIFIED_BY="Jessica Thomas">
<DATE DAY="9" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-02-07 14:41:21 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-09-30 12:51:37 +0100" MODIFIED_BY="Anna Hobson">
<SUMMARY MODIFIED="2015-09-30 12:46:23 +0100" MODIFIED_BY="Anna Hobson">
<TITLE MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">Parasympathomimetic drugs for the treatment of 'dry mouth' due to radiotherapy</TITLE>
<SUMMARY_BODY MODIFIED="2015-09-30 12:46:23 +0100" MODIFIED_BY="Anna Hobson">
<P>This updated review found there is limited evidence to support the use of pilocarpine hydrochloride in the treatment of radiation-induced salivary gland dysfunction ('dry mouth'). Salivary gland damage is a frequent and important complication of radiotherapy to the head and neck area; it causes dryness of the mouth with resultant problems with eating, talking, and local infection. The parasympathomimetic group of drugs have been used to treat radiotherapy-induced salivary gland damage. </P>
<P>We identified three studies that involved a total of 289 participants, and they all used the drug pilocarpine. </P>
<P>The review found that 42% to 51% of participants (4 to 5 in 10) responded to pilocarpine, although in some participants the response did not occur for up to 12 weeks. Pilocarpine was more effective than a placebo treatment, and at least as effective as an artificial saliva. </P>
<P>Side effects were common with pilocarpine (for example sweating, headache, passing urine frequently, flushing), but were usually reported to be mild; 6% to 15% (0.6 to 1.5 in 10) participants had to stop taking pilocarpine due to side effects. </P>
<P>The findings of this review are limited by the small number of good-quality trials that have been performed in this area. The update of this review did not find any new information on this topic.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-09-30 12:35:08 +0100" MODIFIED_BY="Anna Hobson">
<ABS_BACKGROUND MODIFIED="2015-04-20 19:08:15 +0100" MODIFIED_BY="[Empty name]">
<P>This is an updated version of the original Cochrane review on parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy (published in Issue 3, 2007). Salivary gland dysfunction is a predictable side effect of radiotherapy to the head and neck region. Pilocarpine hydrochloride (a choline ester) is licensed in many countries for the treatment of radiation-induced salivary gland dysfunction. Other parasympathomimetics have also been used 'off licence' in the treatment of this condition.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-04-20 19:17:03 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the efficacy and tolerability of parasympathomimetic drugs in the treatment of radiation-induced salivary gland dysfunction (specifically radiation-induced xerostomia).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-09-30 12:34:56 +0100" MODIFIED_BY="Anna Hobson">
<P>For this update, we ran searches of the Cochrane Oral Health Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL 2015, Issue 6), MEDLINE, EMBASE, and CINAHL in July 2015. We checked the reference lists of retrieved articles for additional studies, contacted experts in the field for unpublished and ongoing trials, and contacted relevant pharmaceutical companies for unpublished and ongoing trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>The selection criteria for the review were: 1) randomised controlled trials; 2) people suffering from radiation-induced salivary gland dysfunction; 3) people treated with parasympathomimetic drugs; and 4) assessable data available on primary outcome measure.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>The two review authors independently collected data from the full-text version of relevant papers including: 1) citation details; 2) participants; 3) interventions; 4) assessments; 5) outcomes (that is efficacy, tolerability); and 6) quality issues.</P>
<P>Due to a lack of appropriate data, we were unable to perform a meta-analysis.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>In the original review, three studies, including a total of 298 participants, fulfilled the inclusion criteria. All three studies involved the use of pilocarpine hydrochloride. We have included no additional studies in the update of the review; we have excluded eight additional studies.</P>
<P>The data suggest that pilocarpine hydrochloride is more effective than placebo and at least as effective as artificial saliva. The response rate was 42% to 51%. The time to response was up to 12 weeks. The overall side effect rate was high, and side effects were the main reason for withdrawal (6% to 15% of participants taking 5 mg three times a day had to withdraw). The side effects were usually the result of generalised parasympathomimetic stimulation (for example sweating, headaches, urinary frequency, vasodilatation). Response rates were not dose dependent, but side effect rates were dose dependent.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>There is limited evidence to support the use of pilocarpine hydrochloride in the treatment of radiation-induced xerostomia. Currently, there is little evidence to support the use of other parasympathomimetic drugs in the treatment of radiation-induced xerostomia. Available studies suggest that approximately half of patients will respond, but side effects can be problematic. The conclusions of the update are the same as the conclusions of the original review, since no new relevant studies have been published in the interim.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-09-30 12:51:37 +0100" MODIFIED_BY="Anna Hobson">
<BACKGROUND MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>This review is an update of a previously published review in the Cochrane Database of Systematic Reviews Issue 3, 2007 on 'Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy'.</P>
<CONDITION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Xerostomia has been defined as "the subjective sensation of dryness of the mouth" (<LINK REF="REF-Sreebny-1996" TYPE="REFERENCE">Sreebny 1996</LINK>), whilst salivary gland hypofunction has been defined as "any objectively demonstrable reduction in either whole and/or individual gland flow rates" (<LINK REF="REF-Navazesh-1992" TYPE="REFERENCE">Navazesh 1992</LINK>). Xerostomia is usually the result of a decrease in the volume of saliva secreted. Indeed, normal participants complain of a dry mouth when their unstimulated whole salivary flow rate falls by 50% (<LINK REF="REF-Dawes-1987" TYPE="REFERENCE">Dawes 1987</LINK>). However, xerostomia may also result from a change in the composition of saliva secreted (<LINK REF="REF-Pankhurst-1996" TYPE="REFERENCE">Pankhurst 1996</LINK>). Thus, xerostomia may, or may not, be associated with salivary gland hypofunction. 'Salivary gland dysfunction' is an umbrella term for the presence of either xerostomia or salivary gland hypofunction (<LINK REF="REF-Davies-2005" TYPE="REFERENCE">Davies 2005</LINK>).</P>
<P>Salivary gland dysfunction is a predictable side effect of radiotherapy to the head and neck region (<LINK REF="REF-Guchelaar-1997" TYPE="REFERENCE">Guchelaar 1997</LINK>). It develops soon after the initiation of radiotherapy treatment, progresses during treatment (and for some time after treatment), and is essentially permanent.</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>The treatment of salivary gland dysfunction involves the use of saliva substitutes and saliva stimulants (<LINK REF="REF-Davies-2005" TYPE="REFERENCE">Davies 2005</LINK>):<BR/>
</P>
<UL>
<LI>Saliva substitutes: water, artificial salivas, other substances (e.g. milk). Saliva substitutes can improve xerostomia, but tend not to improve the other problems associated with salivary gland dysfunction.</LI>
<LI>Saliva stimulants: organic acids, chewing gum, parasympathomimetics, other substances (e.g. sugar-free mints). Saliva stimulants can improve xerostomia as well as the other problems associated with salivary gland dysfunction. Moreover, studies suggest that patients find saliva stimulants more effective than saliva substitutes (<LINK REF="REF-Bjornstrom-1990" TYPE="REFERENCE">Bjornstrom 1990</LINK>).</LI>
</UL>
<P>Pilocarpine hydrochloride is licensed in many countries for the treatment of radiation-induced salivary gland dysfunction (<LINK REF="REF-Wiseman-1995" TYPE="REFERENCE">Wiseman 1995</LINK>). Other parasympathomimetics (that is choline esters, cholinesterase inhibitors) have also been used 'off licence' in the treatment of radiation-induced salivary gland dysfunction. This systematic review looked at the effectiveness of parasympathomimetic drugs in the treatment of salivary gland dysfunction (specifically xerostomia) due to radiotherapy.</P>
</INTERVENTION>
<THEORY MODIFIED="2015-04-20 19:22:30 +0100" MODIFIED_BY="[Empty name]">
<P>Parasympathomimetic drugs stimulate muscarinic receptors within the salivary glands, which leads to an increase in saliva secretion.</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Salivary gland dysfunction is associated with a variety of oral problems in this group of patients (for example oral discomfort, taste disturbance, difficulty chewing, difficulty swallowing, speech problems, dental caries, oral candidosis, other oral infections). Indeed, salivary gland dysfunction is associated with a significant impairment of quality of life in this group of patients (<LINK REF="REF-Chambers-2005" TYPE="REFERENCE">Chambers 2005</LINK>). It has been calculated that 93% of patients experience xerostomia during head and neck radiotherapy, and that 74% to 85% of patients experience xerostomia one month to two years postradiotherapy, respectively (<LINK REF="REF-Jensen-2010" TYPE="REFERENCE">Jensen 2010</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>The objectives of this review were to determine the efficacy and tolerability of parasympathomimetic drugs in the treatment of radiation-induced salivary gland dysfunction (specifically radiation-induced xerostomia).</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-09-30 12:51:37 +0100" MODIFIED_BY="Anna Hobson">
<SELECTION_CRITERIA MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<CRIT_STUDIES MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>We considered randomised controlled trials (RCTs) for the previous version of this review and the update. The trials could be of any design (for example parallel group, cross-over), and conducted in any setting (for example inpatient, outpatient). The trials could be published or unpublished, and could be written in any language.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>We considered trials involving participants with radiation-induced salivary gland dysfunction for the previous version of this review and the update. The participants could be of any age, gender, or ethnic origin.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>We considered trials involving parasympathomimetic drugs (that is choline esters, cholinesterase inhibitors) for the previous version of this review and the update. The interventions could be given by any route, formulation, or dose. We considered trials of parasympathomimetic drugs versus no treatment, versus placebo, versus another treatment for salivary gland dysfunction, or versus a combination of the aforementioned options.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>The primary outcome measure of the review was xerostomia, that is the subjective sensation of dryness of the mouth.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>The secondary outcome measures of the review were:</P>
<OL>
<LI>salivary flow rates;</LI>
<LI>adverse effects;</LI>
<LI>other oral symptoms, e.g. oral discomfort, dysgeusia (taste disturbance), dysmasesia (difficulty chewing), dysphagia (difficulty swallowing), dysphonia (difficulty speaking);</LI>
<LI>other oral problems;</LI>
<LI>participant satisfaction;</LI>
<LI>quality of life; and</LI>
<LI>health economics.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-09-30 12:48:40 +0100" MODIFIED_BY="Anna Hobson">
<P>The search strategy was developed for MEDLINE and adapted for the other databases. Please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the search strategies used for this update.</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-09-30 12:48:25 +0100" MODIFIED_BY="Anna Hobson">
<P>For this update we searched the following databases.<BR/>
</P>
<UL>
<LI>Cochrane Oral Health Group Trials Register: searched July 2015.</LI>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Register of Studies Online): searched July 2015 (Issue 6).</LI>
<LI>MEDLINE: 2005 to July 2015.</LI>
<LI>EMBASE: 2005 to July 2015.</LI>
<LI>CINAHL: 2005 to July 2015.</LI>
</UL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-09-30 12:48:40 +0100" MODIFIED_BY="Anna Hobson">
<P>For this update, we searched the metaRegister of Controlled Trials (<A HREF="http://www.controlled-trials.com/mrct">www.controlled-trials.com/mrct</A>), ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>), and the WHO International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://www.who.int/ictrp/en/">http://www.who.int/ictrp/en/</A>) for ongoing trials.</P>
<P>For the previous version of the review and this update, we checked the reference lists of retrieved articles for additional studies, contacted experts in the field for unpublished and ongoing trials, and contacted relevant pharmaceutical companies for unpublished and ongoing trials. We contacted authors for additional information about trials as necessary.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-09-30 12:51:37 +0100" MODIFIED_BY="Anna Hobson">
<STUDY_SELECTION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>For the original version of the review and this update we (two review authors) independently assessed the title or abstract of each record to determine whether or not the paper was relevant to the review. If one or both review authors felt that a paper may be relevant, then we obtained the full-text version of that paper.</P>
<P>Subsequently, we independently assessed the full-text version of each paper to determine whether or not the study met the entry criteria for the review:<BR/>
</P>
<UL>
<LI>RCT;</LI>
<LI>participants suffering from radiation-induced salivary gland dysfunction;</LI>
<LI>participants treated with parasympathomimetic drug;</LI>
<LI>assessable data on primary outcome measure (xerostomia).</LI>
</UL>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>The two review authors independently collected data from the full-text versions of relevant papers using a data extraction form specifically designed for the review. The data collected included:<BR/>
</P>
<UL>
<LI>citation details;</LI>
<LI>details of participants;</LI>
<LI>details of interventions;</LI>
<LI>details of assessment;</LI>
<LI>outcomes, i.e. efficacy, tolerability;</LI>
<LI>quality issues.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Analysis</HEADING>
<P>We were unable to perform a meta-analysis due to a lack of appropriate data. We approached the authors/sponsors (pharmaceutical companies) of relevant studies about the availability of additional data. However, the authors/sponsors (pharmaceutical companies) of these studies were either unable to provide additional data, unwilling to provide additional data, or did not respond to requests for additional data.</P>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-09-30 12:51:37 +0100" MODIFIED_BY="Anna Hobson">
<P>The two review authors independently assessed the risk of bias for each study, using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We resolved any disagreements by discussion. We completed a 'Risk of bias' table for each included study (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). We assessed the following for each study.</P>
<OL>
<LI>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process: random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies using a non-random process, which were therefore at high risk of bias (odd or even date of birth; hospital or clinic record number).</LI>
<LI>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions before assignment determines whether the intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We assessed the methods as: low risk of bias (telephone or central randomisation; consecutively numbered, sealed, opaque envelopes); unclear risk of bias (method not clearly stated). We excluded studies that did not conceal allocation, which were therefore at high risk of bias (open list).</LI>
<LI>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study stated that it was blinded and described the method used to achieve blinding: identical tablets; matched in appearance and smell); unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how blinding was achieved).</LI>
<LI>Incomplete outcome data (attrition bias due to amount, nature, or handling of incomplete outcome data).</LI>
<LI>Reporting bias due to selective outcome reporting.</LI>
</OL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>If we had had appropriate dichotomous data from the studies, we would have used measures such as the risk ratio, odds ratio, risk difference, and number needed to treat to benefit; if we had had appropriate continuous data from the studies, we would have used the mean difference and standardised mean difference.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Two studies were parallel-group studies (<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>), and the participants were independently randomised to one of two groups (that is intervention or placebo); a single measurement from each participant for each outcome measure was collected for analysis. One study, <LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK>, was a cross-over study, and the participants were randomised to an initial group (that is pilocarpine or artificial saliva), and then given the other treatment after a washout period; a single measurement for each treatment period from each participant for each outcome measure was collected for analysis.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>We contacted study authors/sponsors (pharmaceutical companies) to request missing data/data not available in the paper. No such data was forthcoming.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>We were unable to obtain adequate data to carry out a meta-analysis, and so did not consider statistical heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>We employed a comprehensive search strategy and searched multiple databases in order to highlight all relevant published studies. We made efforts to identify unpublished studies, including reviewing clinical trials registers.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Two review authors extracted data from the three included studies using a data extraction form specifically developed for the review. We were unable to obtain the necessary data to perform a meta-analysis.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>We were unable to obtain adequate data to carry out a meta-analysis, and so did not perform subgroup analyses.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>We were unable to obtain adequate data to carry out a meta-analysis, and so did not perform sensitivity analyses.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<STUDY_DESCRIPTION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<SEARCH_RESULTS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>The original version of this review identified 248 references; in this update of the review, we identified a further 82 unique references. One study was written in Hungarian and translated by a Hungarian physician (<LINK REF="STD-Szabo-1985" TYPE="STUDY">Szabo 1985</LINK>). Another study was written in Japanese and translated by a commercial company (on behalf of MGI Pharma Inc) (<LINK REF="STD-Matsumoto-2000" TYPE="STUDY">Matsumoto 2000</LINK>). See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Only three studies fulfilled the entry criteria for the review, and all of these were included in the original version (<LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK>; <LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>). We have summarised details of the included studies in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table, and additional outcome data are available in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<P>All of the included studies were conducted exclusively in people with radiation-induced salivary gland dysfunction. The studies were performed in adults, and appeared to be open to people of any age, gender, or ethnic origin. All the studies were conducted in the outpatient setting. Two studies were conducted in the United States of America (<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>), whilst the remaining study was conducted in the United Kingdom (<LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK>).</P>
<P>Two studies were of parallel-group design (<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>); participants received three months of treatment with either the active drug or the control (placebo). The remaining study was of cross-over design (<LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK>); participants received three months with the active drug and three months with the control (artificial saliva). There was a one-week "washout period" between the treatments.</P>
<P>All of the studies involved the use of pilocarpine hydrochloride. The pilocarpine was given as a tablet in two studies, <LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK> and <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>, and as a mouthwash in the remaining study (<LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK>). The dose of pilocarpine was fixed in two studies (<LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK>; <LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>): in the <LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK> study, all participants received 5 mg three times a day, whilst in the <LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK> study, some participants received 5 mg three times a day and others received 10 mg three times a day. By contrast, in the <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK> study, the dose of pilocarpine was titrated, and could vary between 2.5 to 10 mg three times a day. The pilocarpine dose of was titrated on the basis of efficacy or tolerability, or both.</P>
<P>All of the studies assessed xerostomia: one study, <LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK>, reported absolute changes in visual analogue scale (VAS) scores, whilst the other two studies, <LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK> and <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>, reported the number of participants with greater than 25 mm changes in VAS scores. Other assessments of efficacy included questions about the global effect of the treatment (<LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK>; <LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>), use of other relevant treatments (<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>), and the wish to continue with the treatment (<LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK>).</P>
<P>All of the studies assessed various other oral symptoms, including oral discomfort (<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>), dysgeusia (<LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK>), dysphagia (<LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK>), and dysphonia (<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>). Only two studies measured salivary flow rates (<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>). All of the studies assessed side effects, although only their prevalence, rather than their severity, was reported. None of the studies assessed quality-of-life data or health economics.</P>
<P>Two studies were conducted by a single pharmaceutical company (MGI Pharma Inc, United States of America) (<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>), and one study was conducted by independent researchers (<LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK>).<BR/>
</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>The review authors identified 27 other references relating to unique clinical trials involving parasympathomimetic drugs in the treatment of radiation-induced salivary gland dysfunction: 19 were included in the original review, and 8 were published after the original review.</P>
<P>In the original review:</P>
<UL>
<LI>one was a report of a RCT involving mixed aetiology salivary gland dysfunction; separate data for participants with radiation-induced salivary gland dysfunction was unobtainable (<LINK REF="STD-Fox-1991" TYPE="STUDY">Fox 1991</LINK>);</LI>
<LI>one was a report of provisional results of a RCT; a final report of this study has never been published, and further information was unobtainable (<LINK REF="STD-Schuller-1989" TYPE="STUDY">Schuller 1989</LINK>);</LI>
<LI>four were reports of RCTs with inadequate data on the primary outcome (<LINK REF="STD-Greenspan-1987" TYPE="STUDY">Greenspan 1987</LINK>; <LINK REF="STD-Hamlar-1996" TYPE="STUDY">Hamlar 1996</LINK>; <LINK REF="STD-MacCarthy-1998" TYPE="STUDY">MacCarthy 1998</LINK>; <LINK REF="STD-Gorsky-2004" TYPE="STUDY">Gorsky 2004</LINK>), and further information was unobtainable;</LI>
<LI>one was a report of a RCT with inadequate data on study intervention (i.e. drug doses) (<LINK REF="STD-Frydrych-2002" TYPE="STUDY">Frydrych 2002</LINK>), and further information was unobtainable;</LI>
<LI>12 were reports of uncontrolled studies (see the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table).</LI>
</UL>
<P>In this update:</P>
<UL>
<LI>five were reports of RCTs with inadequate data on the primary outcome (<LINK REF="STD-Abbasi-2013" TYPE="STUDY">Abbasi 2013</LINK>; <LINK REF="STD-Chambers-2007a" TYPE="STUDY">Chambers 2007a</LINK>; <LINK REF="STD-Konno-2007" TYPE="STUDY">Konno 2007</LINK>; <LINK REF="STD-Witsell-2012" TYPE="STUDY">Witsell 2012</LINK>; <LINK REF="STD-Wong-2015" TYPE="STUDY">Wong 2015</LINK>), and further information was unobtainable;</LI>
<LI>three were reports of uncontrolled studies (see the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table).</LI>
</UL>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>See <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>We considered the concealment of allocation low risk of bias in all studies based on information in the published papers (<LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK>; <LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>),</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>We considered blinding high risk of bias in the study by <LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK>, due to the fact that the intervention and control were physically different (making blinding impossible). We considered blinding low risk of bias in the <LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK> and <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK> studies.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>We considered attrition bias low risk in the <LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK> study, and high risk in the other two studies (<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>), the latter due to the fact there were more dropouts in the intervention arms due to adverse effects in these studies.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>We considered reporting bias low risk for all of the studies.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-04-20 19:47:24 +0100" MODIFIED_BY="[Empty name]">
<P>Two of the studies were commercial studies (<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>)</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>We have summarised the results of the included studies in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>In the <LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK> study, the mean improvement in VAS score with pilocarpine was 22.5 mm (100 mm scale), whilst the mean improvement in VAS score with artificial saliva was 15.2 mm. The main side effects reported with the pilocarpine were nausea (20%), sweating (15%), and lacrimation (10%). One participant withdrew from the study definitely because of side effects from the pilocarpine; another participant may have withdrawn from the study because of side effects from the pilocarpine.</P>
<P>In the <LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK> study, a positive response (that is greater than 25 mm change in VAS score) was reported in 25% of participants receiving placebo, 51% of participants receiving pilocarpine 5 mg three times a day, and 47% of participants receiving pilocarpine 10 mg three times a day. The majority of participants responded within four weeks of the start of treatment, although some participants did not respond until eight to 12 weeks. Side effects were common, and the incidence of side effects was dose dependent. The most common side effects at the standard 5 mg three times a day dose were sweating (37%), headache (15%), urinary frequency (14%), vasodilatation (12%), dizziness (10%), dyspepsia (10%), nausea (8%), asthenia (8%), and diarrhoea (5%). Side effects were reported as being "generally mild", although 6% of participants receiving 5 mg three times a day withdrew from the study because of side effects. Twenty-nine percent of participants receiving 10 mg three times a day withdrew from the study because of side effects.</P>
<P>In the <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK> study, a positive response (that is greater than 25 mm change in VAS score) was reported in 7% of participants receiving placebo, and 42% of participants receiving pilocarpine. Side effects were common, and the incidence of side effects was dose dependent. The most common side effects at the standard 5 mg three times a day dose were sweating (21%) and rhinitis (6%). Side effects were reported as being "generally mild", although 15% of participants receiving pilocarpine withdrew from the study because of side effects.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>We have included no new studies in the update of the original review.</P>
<SUMMARY_OF_RESULTS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Data from the original review suggest that pilocarpine hydrochloride can be effective in the management of radiation-induced xerostomia (<LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK>; <LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>). Nevertheless, a significant number of patients do not respond to pilocarpine hydrochloride (49% to 52%) (<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>). Furthermore, the response rate in these studies may not reflect the response rates in the general population. One of the inclusion criteria for the two main studies was "some evidence of residual salivary function" (<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>), which is clearly not a universal finding in people with radiation-induced salivary gland dysfunction. It is reasonable to suppose that people with evidence of salivary gland functioning would be more likely to respond to pilocarpine, since such findings confirm that the salivary glands are still functioning to an extent, and so still capable of responding to a stimulant. Another important consideration is the criterion employed to define a positive response: the researchers adopted a greater than 25 mm change in VAS score, although they did not state the reasons for choosing this particular cutoff point (<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>).</P>
<P>Overall, the response rates were similar for participants taking standard and higher doses (5 mg three times a day, 10 mg three times a day) in the main fixed-dose study (<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>). Nevertheless, some participants only appeared to respond to the higher doses (10 mg three times a day) in the dose titration study (<LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>). There are two possible explanations for the latter finding: a) some participants improved because of the dose increase; or b) some participants improved because of the increase in time on the drug, that is some participants had a delayed response to the drug. It is difficult to determine the importance of these two factors, although it is clear from the data that some participants do have a delayed response to the drug, that is up to 12 weeks (<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>).</P>
<P>The studies highlight the fact that significant numbers of patients develop side effects with pilocarpine hydrochloride. The side effects are usually related to generalised parasympathetic stimulation, and include sweating, headache, urinary frequency, and vasodilatation. The incidence of side effects appears to be related to the dose of the pilocarpine, that is the higher the dose of pilocarpine, the higher the incidence of side effects. For example, the incidence of sweating was 37% at a dose of 5 mg three times a day, but 80% at a dose of 10 mg three times a day (<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>). The severity of side effects may also be related to the dose of pilocarpine; the higher the dose of pilocarpine, the greater the incidence of withdrawals from side effects. For example, the incidence of withdrawals from side effects was 6% at a dose of 5 mg three times a day, but 29% at a dose of 10 mg three times a day (<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>). The reporting of the severity of side effects was minimal, with the authors merely stating that "adverse effects were generally mild" (<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>). Nevertheless, the development of side effects was the predominant reason for withdrawal from the studies (<LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK>; <LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>).</P>
<P>The response to pilocarpine hydrochloride is likely to depend on a number of factors, including degree of damage to the salivary glands (<LINK REF="REF-Guchelaar-1997" TYPE="REFERENCE">Guchelaar 1997</LINK>), concomitant medical problems, concomitant drug treatment, and pharmacokinetic factors. For example, investigators have found an association between response to pilocarpine and levels of serum pilocarpine esterase: people with higher levels of pilocarpine esterase tended to require higher doses of pilocarpine to produce an effect and to experience fewer side effects; people with lower levels of pilocarpine esterase tended to require lower doses of pilocarpine to produce an effect and to experience more side effects (<LINK REF="REF-Aromdee-1996" TYPE="REFERENCE">Aromdee 1996</LINK>).</P>
<P>There is no new data in this update.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>All of the included studies addressed radiotherapy-induced salivary gland dysfunction, and involved the use of the parasympathomimetic drug pilocarpine. All of the studies focused on important outcomes related to this condition, that is xerostomia and related issues, and changes in salivary flow rates. The included studies are all relevant to the review question, and most importantly focus on patient-related outcomes.</P>
<P>Currently, there is little evidence to support the use of other parasympathomimetic drugs in the treatment of radiation-induced xerostomia. Two RCTs investigated cevimeline hydrochloride (<LINK REF="STD-Chambers-2007a" TYPE="STUDY">Chambers 2007a</LINK>; <LINK REF="STD-Witsell-2012" TYPE="STUDY">Witsell 2012</LINK>); these trials suggest that cevimeline may be an effective intervention (<LINK REF="STD-Chambers-2007a" TYPE="STUDY">Chambers 2007a</LINK>), but there is inadequate published data relating to xerostomia (and we have been unable to obtain unpublished data relating to xerostomia).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>The data suggest that pilocarpine hydrochloride is at least as effective as a mucin-based artificial saliva in the management of radiation-induced xerostomia (<LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK>). The improvement in xerostomia was greater with pilocarpine hydrochloride, but this improvement was not statistically significant. It should be noted that this was a small study (that is 20 participants). However, the data suggest that pilocarpine hydrochloride is more effective than the mucin-based artificial saliva in the management of dysgeusia. Data from the other studies confirm that pilocarpine improves not only the xerostomia, but also the associated symptoms of salivary gland dysfunction (that is oral discomfort, dysphonia) (<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>; <LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Due to the comprehensive search strategy and the use of multiple databases, it is very likely that we identified all relevant studies. It was not possible to obtain data from some of the studies identified in the update of this review, hence we could not include them in the review. This could have introduced bias into the review process.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-04-29 14:18:02 +0100" MODIFIED_BY="[Empty name]">
<P>The evidence for this update was systematically reviewed by two authors, and to our knowledge there is no disagreement with other studies or reviews.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<IMPLICATIONS_PRACTICE MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>The conclusions of the updated review are the same as the conclusions of the original review, in spite of the publication of additional RCTs.</P>
<SUBSECTION>
<HEADING LEVEL="5">For people with radiation-induced salivary gland dysfunction:</HEADING>
<P>There is limited evidence to support the use of pilocarpine hydrochloride in the treatment of radiation-induced xerostomia. It would seem appropriate to offer patients a trial of the drug, assuming that there are no contraindications (that is uncontrolled asthma, uncontrolled chronic obstructive pulmonary disease, uncontrolled cardiorenal disease, acute iritis, pregnancy, breast-feeding) to the use of the drug.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">For clinicians:</HEADING>
<P>It would seem appropriate to offer patients a trial of the drug. The trial should be prolonged, since the response can be delayed (up to 12 weeks). The dose used should be 5 mg three times a day to keep side effects to a minimum, since the adverse effects are dose dependent (and the response does not appear to be dose dependent). However, many patients fail to respond to pilocarpine hydrochloride. Currently, there is little evidence to support the use of other parasympathomimetic drugs in the treatment of radiation-induced xerostomia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">For policymakers and funders:</HEADING>
<P>A trial of pilocarpine is recommended for people with symptomatic radiation-induced salivary gland dysfunction, and policymakers/funders should support this option for treatment.<BR/>
</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Additional studies are required to clarify the role of other parasympathomimetic drugs in the treatment of radiation-induced xerostomia. Similarly, additional studies are also required to clarify the role of other interventions in the treatment of radiation-induced xerostomia (for example saliva substitutes, other saliva stimulants). The aim of such studies should be to determine whether these other interventions have greater efficacy or tolerability, or both, as compared to pilocarpine. It is important that future studies focus on the impact of these interventions on the symptoms of salivary gland dysfunction (for example xerostomia, oral discomfort), since these are the 'outcome measures' that determine adherence or non-adherence with treatment. It is equally important that future studies assess the impact of these interventions on the important complications of salivary gland dysfunction (for example dental caries, oral candidosis).</P>
<P>In addition, studies are required in people who have undergone intensity-modulated radiotherapy (and other tissue-sparing techniques) as well as in people who have undergone so-called conventional radiotherapy.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>The search strategy was prepared by Sylvia Bickley, who was the Trials Search Co-ordinator for the Cochrane Pain, Palliative and Supportive Care (PaPaS) Group and the Cochrane Oral Health Group. Anne Littlewood (Trials Search Co-ordinator, Cochrane Oral Health Group) and Jo Abbott (Trials Search Co-ordinator, Cochrane PaPaS Group) updated the searches for the current review. Dr Kate Shorthose was an author for the original review.</P>
<P>Cochrane Review Group funding acknowledgement: The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane PaPaS Group. Disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, National Health Service (NHS), or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Andrew Davies has no relevant conflicts of interest to declare. Jo Thompson has no relevant conflicts of interest to declare.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Andrew Davies: first review author; wrote protocol; reviewed studies; wrote review and update.<BR/>Jo Thompson: second review author; reviewed studies; co-wrote review and update.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>This 2015 update reflects the changes to 'Risk of bias' assessment for included studies.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-09-30 12:51:31 +0100" MODIFIED_BY="Anna Hobson">
<STUDIES MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<INCLUDED_STUDIES MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<STUDY DATA_SOURCE="PUB" ID="STD-Davies-1994" NAME="Davies 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davies AN, Singer J</AU>
<TI>A comparison of artificial saliva and pilocarpine in radiation-induced xerostomia</TI>
<SO>Journal of Laryngology and Otology</SO>
<YR>1994</YR>
<VL>108</VL>
<NO>8</NO>
<PG>663-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-1993" MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NAME="Johnson 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NOTES="&lt;p&gt;et al: Muscoplat CC, Gallagher SC&lt;/p&gt;" NOTES_MODIFIED="2015-09-30 12:34:52 +0100" NOTES_MODIFIED_BY="Anna Hobson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, et al</AU>
<TI>Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>329</VL>
<NO>6</NO>
<PG>390-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;et al: Muscoplat C, Gallagher SC&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rieke JW, Hafermann MD, Johnson JT, LeVeque FG, Iwamoto R, Steiger BW, et al</AU>
<TI>Oral pilocarpine for radiation-induced xerostomia: Integrated efficacy and safety results from two prospective randomized clinical trials</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1995</YR>
<VL>31</VL>
<NO>3</NO>
<PG>661-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LeVeque-1993" MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NAME="LeVeque 1993" YEAR="1993">
<REFERENCE MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NOTES="&lt;p&gt;et al: Gallagher SC, Muscoplat CC&lt;/p&gt;" NOTES_MODIFIED="2015-09-30 12:34:52 +0100" NOTES_MODIFIED_BY="Anna Hobson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>LeVeque FG, Montgomery M, Potter D, Zimmer MB, Rieke JW, Steiger BW</AU>
<TI>A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1993</YR>
<VL>11</VL>
<NO>6</NO>
<PG>1124-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NOTES="&lt;p&gt;et al: Muscoplat C, Gallagher SC&lt;/p&gt;" NOTES_MODIFIED="2015-09-30 12:34:52 +0100" NOTES_MODIFIED_BY="Anna Hobson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rieke JW, Hafermann MD, Johnson JT, LeVeque FG, Iwamoto R, Steiger BW</AU>
<TI>Oral pilocarpine for radiation-induced xerostomia: Integrated efficacy and safety results from two prospective randomized clinical trials</TI>
<SO>International Journal of Radition Oncology, Biology, Physics</SO>
<YR>1995</YR>
<VL>31</VL>
<NO>3</NO>
<PG>661-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Abbasi-2013" MODIFIED="2015-03-08 10:19:35 +0000" MODIFIED_BY="[Empty name]" NAME="Abbasi 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-03-01 14:47:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abbasi F, Farhadi S, Esmaili M</AU>
<TI>Efficacy of pilocarpine and bromhexine in improving radiotherapy-induced xerostomia</TI>
<SO>Dental Research, Dental Clinics, Dental Prospects</SO>
<YR>2013</YR>
<VL>7</VL>
<NO>2</NO>
<PG>86-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-03-08 10:19:35 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-03-08 10:19:35 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.5681/joddd.2013.015"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Chambers-2007a" MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NAME="Chambers 2007a" YEAR="2007">
<REFERENCE MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chambers MS, Posner M, Jones CU, Biel MA, Hodge KM, Vitti R, et al</AU>
<TI>Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2007</YR>
<VL>68</VL>
<NO>4</NO>
<PG>1102-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1016/j.ijrobp.2007.01.019"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chambers-2007b" MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NAME="Chambers 2007b" YEAR="2007">
<REFERENCE MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chambers MS, Jones CU, Biel MA, Weber RS, Hodge KM, Chen Y, et al</AU>
<TI>Open-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomia</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2007</YR>
<VL>69</VL>
<NO>5</NO>
<PG>1369-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-02-01 13:09:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-02-01 13:09:59 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.ijrobp.2007.05.024"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chitapanarux-2008" MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NAME="Chitapanarux 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chitapanarux I, Kamnerdsupaphon P, Tharavichitkul E, Sumitsawan Y, Sittitrai P, Pattaraskulchai T, et al</AU>
<TI>Effect of oral pilocarpine on post-irradiation xerostomia in head and neck cancer patients: a single-center, single-blind clinical trial</TI>
<SO>Journal of Medical Association of Thailand</SO>
<YR>2008</YR>
<VL>91</VL>
<NO>9</NO>
<PG>1410-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-02-01 13:03:26 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cooper-1999" MODIFIED="2015-03-08 10:31:54 +0000" MODIFIED_BY="[Empty name]" NAME="Cooper 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-03-08 10:31:54 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;et al: Slevin NJ, Allan E, Gupta NK, Collins CD&lt;/p&gt;" NOTES_MODIFIED="2015-03-08 10:31:54 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cooper RA, Cowan RA, Owens SE, Jeans SP, Roberts JK, Hillel PG</AU>
<TI>Does salivary gland scintigraphy predict response to pilocarpine in patients with post-radiotherapy xerostomia?</TI>
<SO>European Journal of Nuclear Medicine</SO>
<YR>1999</YR>
<VL>26</VL>
<NO>3</NO>
<PG>220-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Epstein-1987" MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NAME="Epstein 1987" YEAR="1987">
<REFERENCE MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Epstein JB, Schubert MM</AU>
<TI>Synergistic effect of sialagogues in management of xerostomia after radiation therapy</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology</SO>
<YR>1987</YR>
<VL>64</VL>
<NO>2</NO>
<PG>179-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Epstein-1994" MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NAME="Epstein 1994" YEAR="1994">
<REFERENCE MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Epstein JB, Burchell JL, Emerton S, Le ND, Silverman S</AU>
<TI>A clinical trial of bethanechol in patients with xerostomia after radiation therapy. A pilot study</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology</SO>
<YR>1994</YR>
<VL>77</VL>
<NO>6</NO>
<PG>610-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferguson-1991" NAME="Ferguson 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferguson MM, Hayes P, Highton J, Jones DS, MacFadyen EE, Palmer DG</AU>
<TI>Pilocarpine oral solution</TI>
<SO>British Dental Journal</SO>
<YR>1991</YR>
<VL>170</VL>
<NO>7</NO>
<PG>251</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fox-1991" MODIFIED="2015-03-01 15:23:04 +0000" MODIFIED_BY="[Empty name]" NAME="Fox 1991" YEAR="1991">
<REFERENCE MODIFIED="2015-02-01 12:54:42 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;et al: Jackson W, Delapenha RA, Shiroky J, Baum BJ&lt;/p&gt;" NOTES_MODIFIED="2015-02-01 12:54:42 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fox PC, Atkinson JC, Macynski AA, Wolff A, Kung DS, Valdez IH, et al</AU>
<TI>Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia)</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1991</YR>
<VL>151</VL>
<NO>6</NO>
<PG>1149-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Frydrych-2002" NAME="Frydrych 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frydrych AM, Davies GR, Slack-Smith LM, Heywood J</AU>
<TI>An investigation into the use of pilocarpine as a sialagogue in patients with radiation induced xerostomia</TI>
<SO>Australian Dental Journal</SO>
<YR>2002</YR>
<VL>47</VL>
<NO>3</NO>
<PG>249-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gorsky-2004" MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NAME="Gorsky 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gorsky M, Epstein JB, Parry J, Epstein MS, Le ND, Silverman Jr S</AU>
<TI>The efficacy of pilocarpine and bethanechol upon saliva production in cancer patients with hyposalivation following radiation therapy</TI>
<SO>Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics</SO>
<YR>2004</YR>
<VL>97</VL>
<NO>2</NO>
<PG>190-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenspan-1987" MODIFIED="2015-03-27 11:36:35 +0000" MODIFIED_BY="[Empty name]" NAME="Greenspan 1987" YEAR="1987">
<REFERENCE MODIFIED="2015-02-01 12:55:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenspan D, Daniels TE</AU>
<TI>Effectiveness of pilocarpine in postradiation xerostomia</TI>
<SO>Cancer</SO>
<YR>1987</YR>
<VL>59</VL>
<NO>6</NO>
<PG>1123-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamlar-1996" MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NAME="Hamlar 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NOTES="&lt;p&gt;et al: Altman JS, Elzinga DJ, Martin MR&lt;/p&gt;" NOTES_MODIFIED="2015-09-30 12:34:52 +0100" NOTES_MODIFIED_BY="Anna Hobson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamlar DD, Schuller DE, Gahbauer RA, Buerki RA, Staubus AE, Hall J</AU>
<TI>Determination of the efficacy of topical oral pilocarpine for postirradiation xerostomia in patients with head and neck carcinoma</TI>
<SO>Laryngoscope</SO>
<YR>1996</YR>
<VL>106</VL>
<NO>8</NO>
<PG>972-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horiot-2000" MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NAME="Horiot 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NOTES="&lt;p&gt;et al: Bolla M, Coscas Y, Baillet F, Coche-Dequeant B, Urbajtel M, Montbarbon X, Bourdin S, Wibault P, Alfonsi M, Calais G, Desprez P, Pene F, Lapeyre M, Vinke J, Maral J&lt;/p&gt;" NOTES_MODIFIED="2015-09-30 12:34:52 +0100" NOTES_MODIFIED_BY="Anna Hobson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horiot JC, Lipinski F, Schraub S, Maulard-Durdux C, Bensadoun RJ, Ardiet JM</AU>
<TI>Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study</TI>
<SO>Radiotherapy and Oncology</SO>
<YR>2000</YR>
<VL>55</VL>
<NO>3</NO>
<PG>233-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobs-1996" NAME="Jacobs 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs CD, Van Der Pas M</AU>
<TI>A multicenter maintenance study of oral pilocarpine tablets for radiation-induced xerostomia</TI>
<SO>Oncology (Huntington)</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>3 Suppl</NO>
<PG>16-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joensuu-1993" NAME="Joensuu 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joensuu H, Bostrom P, Makkonen T</AU>
<TI>Pilocarpine and carbacholine in treatment of radiation-induced xerostomia</TI>
<SO>Radiotherapy and Oncology</SO>
<YR>1993</YR>
<VL>26</VL>
<NO>1</NO>
<PG>33-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Konno-2007" MODIFIED="2015-03-08 11:44:52 +0000" MODIFIED_BY="[Empty name]" NAME="Konno 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-03-08 10:33:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konno A, Nishio M, Origasa H</AU>
<TI>Oral pilocarpine for radiation-induced xerostomia - a randomized, double-blind, placebo-controlled trial</TI>
<SO>Japanese Pharmacology and Therapeutics</SO>
<YR>2007</YR>
<VL>35 (Suppl 2)</VL>
<PG>S131-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leek-2002" NAME="Leek 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leek H, Albertsson M</AU>
<TI>Pilocarpine treatment of xerostomia in head and neck patients</TI>
<SO>Micron</SO>
<YR>2002</YR>
<VL>33</VL>
<NO>2</NO>
<PG>153-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-MacCarthy-1998" MODIFIED="2015-03-01 15:23:15 +0000" MODIFIED_BY="[Empty name]" NAME="MacCarthy 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-02-01 12:56:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MacCarthy D, Moriarty M, Waldron D</AU>
<TI>The use of pilocarpine HCl in patients with post-radiation xerostomia - Report of a pilot study. (IADR abstract)</TI>
<SO>Journal of Dental Research</SO>
<YR>1998</YR>
<VL>77</VL>
<NO>Spec Iss B</NO>
<PG>979</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matsumoto-2000" MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NAME="Matsumoto 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matsumoto Y</AU>
<TI>Research on delayed damage after radiation therapy for head and neck patients</TI>
<SO>Shika Igaku</SO>
<YR>2000</YR>
<VL>63</VL>
<NO>1</NO>
<PG>15-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mosqueda_x002d_Taylor-2004" NAME="Mosqueda-Taylor 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mosqueda-Taylor A, Luna-Ortiz K, Irigoyen-Camacho ME, Diaz-Franco MA, Coll-Munoz AM</AU>
<TI>Effect of pilocarpine hydrochloride on salivary production in previously irradiated head and neck cancer patients</TI>
<TO>Efecto del clorhidrato de pilocarpina como estimulante de la produccion salival en pacientes sometidos a radioterapia de cabeza y cuello</TO>
<SO>Medicina Oral</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>3</NO>
<PG>204-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nakamura-2009" MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NAME="Nakamura 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakamura N, Sasano N, Yamashita H, Igaki H, Shiraishi K, Terahara A, et al</AU>
<TI>Oral pilocarpine (5mg t.i.d) used for xerostomia causes adverse effects in Japanese</TI>
<SO>Auris Nasus Larynx</SO>
<YR>2009</YR>
<VL>36(3)</VL>
<PG>310-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-02-01 12:59:18 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-02-01 12:59:18 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.anl.2008.04.008"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schuller-1989" NAME="Schuller 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schuller DE, Stevens P, Clausen KP, Olsen J, Gahbauer R, Martin M</AU>
<TI>Treatment of radiation side effects with oral pilocarpine</TI>
<SO>Journal of Surgical Oncology</SO>
<YR>1989</YR>
<VL>42</VL>
<NO>4</NO>
<PG>272-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singhal-1997" NAME="Singhal 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singhal S, Powles R, Treleaven J, Rattenbury H, Mehta J</AU>
<TI>Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies</TI>
<SO>Leukemia and Lymphoma</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>5-6</NO>
<PG>539-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szabo-1985" NAME="Szabo 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Szabo G</AU>
<TI>Treatment of xerostomia with pilocarpine. Based on 15 years experience and treatment of 500 patients</TI>
<TO>Xerostomia kezelese Pilocarpinnal</TO>
<SO>Fogorvosi Szemle</SO>
<YR>1985</YR>
<VL>78</VL>
<NO>3</NO>
<PG>65-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Witsell-2012" MODIFIED="2015-07-28 10:21:57 +0100" MODIFIED_BY="[Empty name]" NAME="Witsell 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-03-08 10:36:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Witsell D, Stinnett S, Chambers MS</AU>
<TI>Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia</TI>
<SO>Head and Neck</SO>
<YR>2012</YR>
<VL>34(8)</VL>
<PG>1136-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-07-28 10:21:57 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-07-28 10:21:57 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/hed.21894"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wong-2015" MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NAME="Wong 2015" YEAR="2015">
<REFERENCE MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" PRIMARY="YES" TYPE="OTHER">
<AU>Wong RK, Deshmukh S, Wyatt G, Sagar S, Singh AK, Sultanem K, et al</AU>
<TI>Acupuncture-like transcutaneous electrical nerve stimulation versus pilocarpine in treating radiation-induced xerostomia: results of RTOG 0537 phase 3 study</TI>
<SO>International Journal of Radiation Oncology Biology Physics</SO>
<YR>2015 [Epub ahead of print]</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-07-28 10:32:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-07-28 10:24:59 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="doi: 10.1016/j.ijrobp.2015.01.050"/>
</IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-07-28 10:15:34 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2015-03-01 19:10:27 +0000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-09-30 12:51:31 +0100" MODIFIED_BY="Anna Hobson">
<ADDITIONAL_REFERENCES MODIFIED="2015-09-30 12:51:31 +0100" MODIFIED_BY="Anna Hobson">
<REFERENCE ID="REF-Aromdee-1996" NAME="Aromdee 1996" TYPE="JOURNAL_ARTICLE">
<AU>Aromdee C, Fawcett JP, Ferguson MM, Ledger R</AU>
<TI>Serum pilocarpine esterase activity and response to oral pilocarpine</TI>
<SO>Biochemical and Molecular Medicine</SO>
<YR>1996</YR>
<VL>59</VL>
<NO>1</NO>
<PG>57-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bjornstrom-1990" NAME="Bjornstrom 1990" TYPE="JOURNAL_ARTICLE">
<AU>Bjornstrom M, Axell T, Birkhed D</AU>
<TI>Comparison between saliva stimulants and saliva substitutes in patients with symptoms related to dry mouth. A multi-centre study</TI>
<SO>Swedish Dental Journal</SO>
<YR>1990</YR>
<VL>14</VL>
<NO>4</NO>
<PG>153-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chambers-2005" MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NAME="Chambers 2005" TYPE="BOOK_SECTION">
<AU>Chambers M, Garden A, Lemon J, Kies M, Martin J</AU>
<TI>Oral complications of cancer treatment</TI>
<SO>Oral Care in Advanced Disease</SO>
<YR>2005</YR>
<PG>171-84</PG>
<ED>Davies A, Finlay I</ED>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davies-2005" MODIFIED="2015-09-11 06:54:31 +0100" MODIFIED_BY="[Empty name]" NAME="Davies 2005" TYPE="BOOK_SECTION">
<AU>Davies A</AU>
<TI>Salivary gland dysfunction</TI>
<SO>Oral Care in Advanced Disease</SO>
<YR>2005</YR>
<PG>97-113</PG>
<ED>Davies A, Finlay I</ED>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dawes-1987" NAME="Dawes 1987" TYPE="JOURNAL_ARTICLE">
<AU>Dawes C</AU>
<TI>Physiological factors affecting salivary flow rates, oral sugar clearance, and the sensation of dry mouth in man</TI>
<SO>Journal of Dental Research</SO>
<YR>1987</YR>
<VL>66</VL>
<NO>Spec Iss</NO>
<PG>648-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guchelaar-1997" NAME="Guchelaar 1997" TYPE="JOURNAL_ARTICLE">
<AU>Guchelaar H-J, Vermes A, Meerwaldt JH</AU>
<TI>Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment</TI>
<SO>Supportive Care in Cancer</SO>
<YR>1997</YR>
<VL>5</VL>
<NO>4</NO>
<PG>281-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-09-30 12:51:31 +0100" MODIFIED_BY="Anna Hobson" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</SO>
<YR>2011</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jensen-2010" MODIFIED="2015-04-16 09:58:54 +0100" MODIFIED_BY="[Empty name]" NAME="Jensen 2010" TYPE="JOURNAL_ARTICLE">
<AU>Jensen SB, Pedersen AML, Vissink A, Andersen E, Brown CG, Davies AN, et al</AU>
<TI>A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life</TI>
<SO>Supportive Care in Cancer</SO>
<YR>2010</YR>
<VL>18</VL>
<PG>1039-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Navazesh-1992" NAME="Navazesh 1992" TYPE="JOURNAL_ARTICLE">
<AU>Navazesh M, Christensen C, Brightman V</AU>
<TI>Clinical criteria for the diagnosis of salivary gland hypofunction</TI>
<SO>Journal of Dental Research</SO>
<YR>1992</YR>
<VL>71</VL>
<NO>7</NO>
<PG>1363-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pankhurst-1996" NAME="Pankhurst 1996" TYPE="JOURNAL_ARTICLE">
<AU>Pankhurst CL, Smith EC, Rogers JO, Dunne SM, Jackson SH, Proctor G</AU>
<TI>Diagnosis and management of the dry mouth: Part 1</TI>
<SO>Dental Update</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>2</NO>
<PG>56-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-04-29 14:52:25 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Cochrane Collaboration</PB>
<CY>The Nordic Cochrane Centre, Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sreebny-1996" MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NAME="Sreebny 1996" TYPE="BOOK_SECTION">
<AU>Sreebny LM</AU>
<TI>Xerostomia: diagnosis, management and clinical complications</TI>
<SO>Saliva and Oral Health</SO>
<YR>1996</YR>
<PG>43-66</PG>
<EN>2nd</EN>
<ED>Edgar WM, O'Mullane DM</ED>
<PB>British Dental Association</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wiseman-1995" NAME="Wiseman 1995" TYPE="JOURNAL_ARTICLE">
<AU>Wiseman LR, Faulds D</AU>
<TI>Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia</TI>
<SO>Drugs</SO>
<YR>1995</YR>
<VL>49</VL>
<NO>1</NO>
<PG>143-55</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Davies-1994">
<CHAR_METHODS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Randomised controlled trial<BR/>Cross-over design<BR/>Unblinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>20 outpatients<BR/>12 male, 8 female<BR/>Mean age 63 yrs (range 46 to 82 yrs)<BR/>16 carcinomas, 4 lymphomas<BR/>Mean dose radiotherapy 55 Gy (range 35 to 65 Gy)<BR/>Mean time since radiotherapy - not stated<BR/>Inclusion criteria - not stated<BR/>Exclusion criteria - not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Pilocarpine mouthwash 5 mg 3 times a day<BR/>Saliva Orthana spray (mucin-based artificial saliva) 2 to 3 sprays when necessary<BR/>Each treatment used for 3 months (1 week washout period)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Primary outcome (xerostomia):</P>
<P>Measured using participant-rated VAS (100 mm VAS, higher scores representing less xerostomia). Change in 100 mm VAS from baseline to end of treatment period.</P>
<P>Pilocarpine - mean +22.5 mm<BR/>Saliva Orthana - mean +15.2 mm</P>
<P>Secondary outcomes: dysphagia, dysgeusia, adverse effects</P>
<P>Change in 100 mm VAS from baseline to end of treatment period</P>
<P>Withdrawals</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Original trial data could not be traced.<BR/>Data on efficacy relates to those participants who completed the study (17/20 participants).<BR/>No period/carry-over effect reported.<BR/>The improvement in xerostomia was not statistically significant.<BR/>The paper reports that 10/17 participants preferred the pilocarpine, 4/17 preferred the Saliva Orthana, and 3/17 had no preference; 8/17 participants wanted to continue with the pilocarpine, 3/17 wanted to continue with the Saliva Orthana, and 6/17 did not want to continue with either treatment after the trial.<BR/>It is unclear what treatment 1 participant was taking when they were withdrawn from the study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Johnson-1993">
<CHAR_METHODS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Randomised controlled trial<BR/>Parallel-group design<BR/>Double blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>207 outpatients</P>
<P>142 male, 65 female</P>
<P>Mean age 58 yrs (range - not stated)</P>
<P>Diagnoses - head and neck cancer</P>
<P>Mean dose radiotherapy 62 Gy (range 40 to 75 Gy)</P>
<P>Mean time since radiotherapy 978 days</P>
<P>Inclusion criteria:</P>
<OL>
<LI>Radiotherapy dose &gt; 40 Gy</LI>
<LI>Radiotherapy &gt; 4 months previously</LI>
<LI>At least 1 parotid gland present</LI>
<LI>Clinically significant xerostomia</LI>
<LI>Evidence of salivary gland functioning on examination</LI>
</OL>
<P>Exclusion criteria:</P>
<OL>
<LI>Concurrent "clinically important uncontrolled cardiac, renal, and pulmonary disease"</LI>
<LI>Concurrent "other chronic diseases that could potentially interfere with the evaluation" of the drug</LI>
<LI>Concurrent ocular disease</LI>
<LI>Concurrent use of tricyclic antidepressants, antihistamines with anticholinergic effects, beta blockers, pilocarpine eye preparations</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Pilocarpine tablets 5 mg or 10 mg three times a day (fixed dose)<BR/>Placebo 1 tablet three times a day<BR/>Treatment period 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Primary outcome (xerostomia):</P>
<P>Measured using participant-rated VAS (100 mm VAS, higher scores representing less xerostomia) at baseline (before the start of treatment) and every 4 weeks.<BR/>Participants with a &gt; +25 mm change in 100 mm VAS from baseline to end of treatment period were classified as having responded.<BR/>
</P>
<P>Secondary outcomes (oral discomfort, speaking ability, overall condition, adverse effects):</P>
<P>Measured using participant-rated VAS (100 mm VAS)<BR/>
<BR/>Withdrawals:<BR/>Pilocarpine 5 mg -<BR/>8 (11%) participants - 4 adverse effects, 2 protocol deviation, 1 non-concordance, 1 personal reasons<BR/>Pilocarpine 10 mg -<BR/>27 (39%) participants - 20 adverse effects, 3 personal reasons, 2 lack of effect, 1 protocol deviation, 1 "other"<BR/>Placebo -<BR/>6 (9%) participants - 2 adverse effects, 2 lack of efficacy, 1 non-concordance, 1 personal reasons</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Drug company declined to supply additional trial data.<BR/>The paper reports decrease in the use of saliva substitutes/other agents in 18/69 participants using pilocarpine 5 mg, 18/52 participants using pilocarpine 10 mg, and 5/62 participants using placebo.<BR/>The majority of participants responded within 4 weeks of the start of treatment, although some participants did not respond until 8 to 12 weeks.<BR/>The paper reports that "adverse effects were generally mild".</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-LeVeque-1993">
<CHAR_METHODS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Randomised controlled trial<BR/>Parallel-group design<BR/>Double blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>162 outpatients</P>
<P>115 male, 47 female</P>
<P>Mean age 58 yrs (range - not stated)</P>
<P>Diagnoses - head and neck cancer</P>
<P>Mean dose radiotherapy 60 Gy (range not stated)</P>
<P>Mean time since radiotherapy 914 days</P>
<P>Inclusion criteria:</P>
<OL>
<LI>Radiotherapy dose &gt; 50 Gy</LI>
<LI>Radiotherapy &gt; 4 months previously</LI>
<LI>At least 1 parotid gland present</LI>
<LI>Clinically significant xerostomia</LI>
<LI>Evidence of salivary gland functioning on examination</LI>
</OL>
<P>Exclusion criteria:</P>
<OL>
<LI>Diagnosis of lymphoma</LI>
<LI>Concurrent "clinically significant uncontrolled cardiac, renal, or pulmonary disease"</LI>
<LI>Concurrent "other chronic diseases that could potentially interfere with the evaluation" of the drug</LI>
<LI>Concurrent ocular disease</LI>
<LI>Concurrent use of tricyclic antidepressants, antihistamines with anticholinergic effects, beta blockers, pilocarpine eye preparations</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Pilocarpine tablets 2.5 mg, 5 mg, or 10 mg three times a day (dose titrated)<BR/>Placebo 1 tablet three times a day (dose titrated)<BR/>Treatment period 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Primary outcome (xerostomia):<BR/>Measured using participant-rated VAS (100 mm VAS, higher scores representing less xerostomia) at baseline (before the start of treatment) and every 4 weeks.<BR/>Participants with a &gt; +25 mm change in 100 mm VAS from baseline to end of treatment period were classified as having responded.<BR/>
</P>
<P>Secondary outcomes (oral discomfort, speaking ability, overall condition, adverse effects):<BR/>Measured using participant-rated VAS (100 mm VAS, higher scores representing less xerostomia) at baseline (before the start of treatment) and every 4 weeks.<BR/>
</P>
<P>
<BR/>
</P>
<P>Withdrawals:<BR/>Pilocarpine -<BR/>12 (16%) participants - 11 adverse effects, 1 personal reasons<BR/>Placebo -<BR/>18 (21%) participants - 9 adverse effects, 3 lack of effect, 3 personal reasons, 1 protocol deviation, 1 non-concordance, 1 "other"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Drug company declined to supply additional trial data.<BR/>The participants did not respond to the 2.5 mg dose of pilocarpine.<BR/>The paper reports decrease in use of saliva substitutes/other agents in 18/69 participants using pilocarpine and 10/77 participants using placebo.<BR/>The paper reports that "adverse effects were generally mild".</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>VAS: visual analogue scale</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Abbasi-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>RCT comparing oral pilocarpine and oral bromhexine. No robust data available on primary outcome (xerostomia)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Chambers-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>RCT comparing oral cevimeline and placebo. No robust data available on primary outcome (xerostomia)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-08 12:11:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chambers-2007b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-08 12:11:25 +0000" MODIFIED_BY="[Empty name]">
<P>Uncontrolled study of oral cevimeline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-08 12:11:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chitapanarux-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-08 12:11:50 +0000" MODIFIED_BY="[Empty name]">
<P>Uncontrolled study of oral pilocarpine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cooper-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of oral pilocarpine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Epstein-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of oral pilocarpine together with oral antholetrithione</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Epstein-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of oral bethanechol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ferguson-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of oral pilocarpine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Fox-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>RCT comparing oral pilocarpine and placebo. Data only available on all participants randomised to study (mixed aetiology salivary gland dysfunction)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Frydrych-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>RCT comparing topical pilocarpine and artificial saliva. No robust data available on doses of pilocarpine used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Gorsky-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>RCT comparing oral pilocarpine and oral bethanechol. No robust data available on primary outcome (xerostomia)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Greenspan-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>RCT comparing oral pilocarpine and placebo. No robust data available on primary outcome (xerostomia)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Hamlar-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>RCT comparing topical pilocarpine and placebo. No data available on primary outcome (xerostomia)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Horiot-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of oral pilocarpine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jacobs-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of oral pilocarpine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Joensuu-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of oral pilocarpine and oral carbacholine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Konno-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>RCT comparing oral pilocarpine and placebo. No robust data available on primary outcome (xerostomia)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leek-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of oral pilocarpine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-MacCarthy-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>Abstract. RCT comparing oral pilocarpine and placebo. No data available on primary outcome (xerostomia)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Matsumoto-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of oral pilocarpine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mosqueda_x002d_Taylor-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of oral pilocarpine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-03-08 12:15:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nakamura-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-03-08 12:15:41 +0000" MODIFIED_BY="[Empty name]">
<P>Uncontrolled study of oral pilocarpine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Schuller-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>RCT comparing oral pilocarpine and placebo. Data only available on initial participants randomised to study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Singhal-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of oral pilocarpine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Szabo-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Uncontrolled study of parenteral pilocarpine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Witsell-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>RCT comparing oral cevimeline and placebo. No robust data available on primary outcome (xerostomia)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" STUDY_ID="STD-Wong-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<P>RCT comparing oral pilocarpine and acupuncture-like transcutaneous electrical nerve stimulation. No robust data available on primary outcome (xerostomia)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT: randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-07-28 10:57:29 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-03-01 19:10:27 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Davies-1994">
<DESCRIPTION>
<P>Study's primary author reports that participants were adequately randomised to reduce risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-17 15:00:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1993">
<DESCRIPTION>
<P>"Patients were assigned randomly with computer-generated randomisation codes with a block of six"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-LeVeque-1993">
<DESCRIPTION>
<P>"A computer-generated randomisation code with a block of six was used"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-17 14:48:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davies-1994">
<DESCRIPTION>
<P>Study's primary author reports that allocation concealment was adequate to reduce risk of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-17 15:00:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1993">
<DESCRIPTION>
<P>"Patients were assigned randomly with computer-generated randomisation codes with a block of six"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-LeVeque-1993">
<DESCRIPTION>
<P>"A computer-generated randomisation code with a block of six was used"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2015-05-17 16:11:28 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-17 14:24:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Davies-1994">
<DESCRIPTION>
<P>Open study comparing an oral tablet and an oral spray</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-17 15:02:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1993">
<DESCRIPTION>
<P>"The study was conducted in double blind fashion, and the code was not broken until the study was completed"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-17 16:11:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LeVeque-1993">
<DESCRIPTION>
<P>"The placebo tablets used in this study were an inert, cellulose and stearic acid composition identical to the active agent in size, colour and overall appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2015-05-17 16:11:50 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-17 14:24:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Davies-1994">
<DESCRIPTION>
<P>Open study comparing an oral tablet and an oral spray</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-17 15:03:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1993">
<DESCRIPTION>
<P>"The study was conducted in double blind fashion, and the code was not broken until the study was completed"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-17 16:11:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LeVeque-1993">
<DESCRIPTION>
<P>"The placebo tablets used in this study were an inert, cellulose and stearic acid composition identical to the active agent in size, colour and overall appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2015-05-17 16:11:59 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-04-17 14:24:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Davies-1994">
<DESCRIPTION>
<P>Open study comparing an oral tablet and an oral spray</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-17 15:05:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1993">
<DESCRIPTION>
<P>"The study was conducted in double blind fashion, and the code was not broken until the study was completed"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-17 16:11:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LeVeque-1993">
<DESCRIPTION>
<P>"The placebo tablets used in this study were an inert, cellulose and stearic acid composition identical to the active agent in size, colour and overall appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NO="12">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Davies-1994">
<DESCRIPTION>
<P>Data on efficacy relates to 17/20 participants. 17/20 participants finished the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-17 15:11:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Johnson-1993">
<DESCRIPTION>
<P>Higher number of dropouts in intervention group compared to control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" RESULT="NO" STUDY_ID="STD-LeVeque-1993">
<DESCRIPTION>
<P>Dropouts: 12 pilocarpine/18 control</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="STUDY" MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" NO="13">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-21 15:09:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davies-1994">
<DESCRIPTION>
<P>Primary and secondary outcomes have been reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-09-30 12:34:52 +0100" MODIFIED_BY="Anna Hobson" RESULT="YES" STUDY_ID="STD-Johnson-1993">
<DESCRIPTION>
<P>Primary and secondary outcomes have been reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-05-17 16:22:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-LeVeque-1993">
<DESCRIPTION>
<P>Primary and secondary outcomes have been reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2015-09-30 12:34:53 +0100" MODIFIED_BY="Anna Hobson">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-07-28 10:51:39 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram for review update</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAloAAAKDCAYAAADCaqQNAABO5UlEQVR42u3dD4RW6f/H/y9ZSVYi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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-09-30 12:34:53 +0100" MODIFIED_BY="Anna Hobson" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-09-30 12:34:53 +0100" MODIFIED_BY="Anna Hobson" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATsAAAGvCAIAAACrSeXFAAASiElEQVR42u3dMY4cNxOG4T2AAgU6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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-09-30 12:59:34 +0100" MODIFIED_BY="Anna Hobson">
<APPENDIX ID="APP-01" MODIFIED="2015-09-25 14:50:49 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-05-20 16:35:55 +0100" MODIFIED_BY="[Empty name]">Search strategies for the 2015 update</TITLE>
<APPENDIX_BODY MODIFIED="2015-09-25 14:50:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>CENTRAL (CRSO)</B>
</P>
<P>MESH DESCRIPTOR Radiotherapy</P>
<P>radioth*:TI,AB,KY</P>
<P>radiat*:TI,AB,KY</P>
<P>irradiat*:TI,AB,KY</P>
<P>#1 OR #2 OR #3 OR #4</P>
<P>MESH DESCRIPTOR Xerostomia</P>
<P>xerostomi*:TI,AB,KY</P>
<P>radioxerost*:TI,AB,KY</P>
<P>("dry mouth"):TI,AB,KY</P>
<P>("salivary gland hypofunction"):TI,AB,KY</P>
<P>( "salivary gland dysfunction"):TI,AB,KY</P>
<P>saliv*:TI,AB,KY</P>
<P>#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12</P>
<P>MESH DESCRIPTOR Parasympathomimetics</P>
<P>MESH DESCRIPTOR Cholinergic Agonists</P>
<P>MESH DESCRIPTOR Acetylcholine</P>
<P>MESH DESCRIPTOR Bethanechol Compounds</P>
<P>MESH DESCRIPTOR Bethanechol</P>
<P>MESH DESCRIPTOR Carbachol</P>
<P>MESH DESCRIPTOR Methacholine Chloride</P>
<P>MESH DESCRIPTOR Pilocarpine</P>
<P>MESH DESCRIPTOR Cholinesterase Inhibitors</P>
<P>MESH DESCRIPTOR Ambenonium Chloride</P>
<P>MESH DESCRIPTOR Edrophonium</P>
<P>MESH DESCRIPTOR Neostigmine</P>
<P>MESH DESCRIPTOR Paraoxon</P>
<P>MESH DESCRIPTOR Physostigmine</P>
<P>MESH DESCRIPTOR Pyridostigmine Bromide</P>
<P>parasympathomimetic*:TI,AB,KY</P>
<P>(choline esters):TI,AB,KY</P>
<P>cholinomimetics:TI,AB,KY</P>
<P>(aceclidine hydrochloride):TI,AB,KY</P>
<P>acetylcholine:TI,AB,KY</P>
<P>(bethanechol chloride):TI,AB,KY</P>
<P>carbachol:TI,AB,KY</P>
<P>(choline alfoscerate):TI,AB,KY</P>
<P>(choline alfoscerate):TI,AB,KY</P>
<P>(methacholine chloride):TI,AB,KY</P>
<P>pilocarpine:TI,AB,KY</P>
<P>(cholinesterase inhibitor*):TI,AB,KY</P>
<P>anticholinesterases:TI,AB,KY</P>
<P>ambenonium:TI,AB,KY</P>
<P>(demecarium bromide):TI,AB,KY</P>
<P>distigmine:TI,AB,KY</P>
<P>edrophonium:TI,AB,KY</P>
<P>(eseridine salicylate):TI,AB,KY</P>
<P>(eseridine salicylate):TI,AB,KY</P>
<P>(galantamine hydrobromide):TI,AB,KY</P>
<P>neostigmine:TI,AB,KY</P>
<P>paraoxon:TI,AB,KY</P>
<P>physostigmine:TI,AB,KY</P>
<P>pyridostigmine:TI,AB,KY</P>
<P>cevimeline:TI,AB,KY</P>
<P>#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53</P>
<P>#5 AND #13 AND #54</P>
<P>2005 TO 2015:</P>
<P>#55 AND #56</P>
<P>
<B>MEDLINE (OVID)</B>
</P>
<P>1. Radiotherapy/</P>
<P>2. radioth*.mp.</P>
<P>3. radiat*.mp.</P>
<P>4. irradiat*.mp.</P>
<P>5. or/1-4</P>
<P>6. Xerostomia/</P>
<P>7. xerostomi*.mp.</P>
<P>8. radioxerost*.mp.</P>
<P>9. "dry mouth".mp.</P>
<P>10. "salivary gland hypofunction".mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>11. "salivary gland dysfunction".mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>12. saliv*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>13. or/6-12</P>
<P>14. Parasympathomimetics/</P>
<P>15. Cholinergic Agonists/</P>
<P>16. Acetylcholine/</P>
<P>17. Bethanechol Compounds/</P>
<P>18. Bethanechol/</P>
<P>19. Carbachol/</P>
<P>20. Methacholine Chloride/</P>
<P>21. Pilocarpine/</P>
<P>22. Cholinesterase Inhibitors/</P>
<P>23. Ambenonium Chloride/</P>
<P>24. Edrophonium/</P>
<P>25. Neostigmine/</P>
<P>26. Paraoxon/</P>
<P>27. Physostigmine/</P>
<P>28. Pyridostigmine Bromide/</P>
<P>29. parasympathomimetic*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>30. choline esters.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>31. cholinomimetics.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>32. aceclidine hydrochloride.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>33. acetylcholine.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>34. bethanechol chloride.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>35. carbachol.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>36. choline alfoscerate.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>37. methacholine chloride.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>38. pilocarpine.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>39. cholinesterase inhibitor*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>40. anticholinesterases.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>41. ambenonium.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>42. demecarium bromide.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>43. distigmine.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>44. edrophonium.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>45. eseridine salicylate.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>46. galantamine hydrobromide.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>47. neostigmine.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>48. paraoxon.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>49. physostigmine.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>50. pyridostigmine.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>51. cevimeline.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]</P>
<P>52. or/14-51</P>
<P>53. 5 and 13 and 52</P>
<P>54. randomized controlled trial.pt.</P>
<P>55. controlled clinical trial.pt.</P>
<P>56. randomized.ab.</P>
<P>57. placebo.ab.</P>
<P>58. drug therapy.fs.</P>
<P>59. randomly.ab.</P>
<P>60. trial.ab.</P>
<P>61. groups.ab.</P>
<P>62. 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61</P>
<P>63. exp animals/ not humans.sh.</P>
<P>64. 62 not 63</P>
<P>65. 53 and 64</P>
<P>66. (2005* or 2006* or 2007* or 2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014* or 2015*).ed.</P>
<P>67. 65 and 66</P>
<P>
<B>EMBASE (OVID)</B>
</P>
<P>1. Radiotherapy/</P>
<P>2. radioth*.mp.</P>
<P>3. radiat*.mp.</P>
<P>4. irradiat*.mp.</P>
<P>5. or/1-4</P>
<P>6. Xerostomia/</P>
<P>7. xerostomi*.mp.</P>
<P>8. radioxerost*.mp.</P>
<P>9. "dry mouth".mp.</P>
<P>10. "salivary gland hypofunction".mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>11. "salivary gland dysfunction".mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>12. saliv*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>13. or/6-12</P>
<P>14. Parasympathomimetics/</P>
<P>15. Cholinergic Agonists/</P>
<P>16. Acetylcholine/</P>
<P>17. Bethanechol Compounds/</P>
<P>18. Bethanechol/</P>
<P>19. Carbachol/</P>
<P>20. Methacholine Chloride/</P>
<P>21. Pilocarpine/</P>
<P>22. Cholinesterase Inhibitors/</P>
<P>23. Ambenonium Chloride/</P>
<P>24. Edrophonium/</P>
<P>25. Neostigmine/</P>
<P>26. Paraoxon/</P>
<P>27. Physostigmine/</P>
<P>28. Pyridostigmine Bromide/</P>
<P>29. parasympathomimetic*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>30. choline esters.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>31. cholinomimetics.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>32. aceclidine hydrochloride.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>33. acetylcholine.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>34. bethanechol chloride.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>35. carbachol.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>36. choline alfoscerate.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>37. methacholine chloride.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>38. pilocarpine.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>39. cholinesterase inhibitor*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>40. anticholinesterases.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>41. ambenonium.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>42. demecarium bromide.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>43. distigmine.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>44. edrophonium.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>45. eseridine salicylate.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>46. galantamine hydrobromide.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>47. neostigmine.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>48. paraoxon.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>49. physostigmine.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>50. pyridostigmine.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>51. cevimeline.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>52. or/14-51</P>
<P>53. 5 and 13 and 52</P>
<P>54. random$.tw.</P>
<P>55. factorial$.tw.</P>
<P>56. crossover$.tw.</P>
<P>57. cross over$.tw.</P>
<P>58. cross-over$.tw.</P>
<P>59. placebo$.tw.</P>
<P>60. (doubl$ adj blind$).tw.</P>
<P>61. (singl$ adj blind$).tw.</P>
<P>62. assign$.tw.</P>
<P>63. allocat$.tw.</P>
<P>64. volunteer$.tw.</P>
<P>65. Crossover Procedure/</P>
<P>66. double-blind procedure.tw.</P>
<P>67. Randomized Controlled Trial/</P>
<P>68. Single Blind Procedure/</P>
<P>69. or/54-68</P>
<P>70. (animal/ or nonhuman/) not human/</P>
<P>71. 69 not 70</P>
<P>72. 53 and 71</P>
<P>73. (2005* or 2006* or 2007* or 2008* or 2009* or 2010* or 2011* or 2012* or 2013* or 2014* or 2015*).dd.</P>
<P>74. 72 and 73</P>
<P>
<B>CINAHL (EBSCO)</B>
</P>
<P>S52 S50 AND S51</P>
<P>S51 EM 20050201-20140630</P>
<P>S50 S15 AND S49</P>
<P>S49 S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33</P>
<P>OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48</P>
<P>S48 cevimeline</P>
<P>S47 pyridostigmine</P>
<P>S46 physostigmine</P>
<P>S45 paraoxon</P>
<P>S44 neostigmine</P>
<P>S43 (galantamine hydrobromide)</P>
<P>S42 (eseridine salicylate)</P>
<P>S41 edrophonium</P>
<P>S40 distigmine</P>
<P>S39 (demecarium bromide)</P>
<P>S38 ambenonium</P>
<P>S37 anticholinesterases</P>
<P>S36 (cholinesterase inhibitor*)</P>
<P>S35 pilocarpine</P>
<P>S34 (methacholine chloride)</P>
<P>S33 (choline alfoscerate)</P>
<P>S32 carbachol</P>
<P>S31 (bethanechol chloride)</P>
<P>S30 acetylcholine</P>
<P>S29 (aceclidine hydrochloride)</P>
<P>S28 cholinomimetics</P>
<P>S27 (choline esters)</P>
<P>S26 parasympathomimetic*</P>
<P>S25 (MH "Physostigmine")</P>
<P>S24 (MH "Neostigmine")</P>
<P>S23 (MH "Cholinesterase Inhibitors")</P>
<P>S22 (MH "Pilocarpine")</P>
<P>S21 (MH "Methacholine Chloride")</P>
<P>S20 (MH "Bethanechol")</P>
<P>S19 (MH "Bethanechol Compounds")</P>
<P>S18 (MH "Acetylcholine")</P>
<P>S17 (MH "Cholinergic Agonists")</P>
<P>S16 (MH "Parasympathomimetics")</P>
<P>S15 S5 AND S14</P>
<P>S14 S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13</P>
<P>S13 saliv*</P>
<P>S12 "salivary gland dysfunction"</P>
<P>S11 "salivary gland hypofunction"</P>
<P>S10 ("dry mouth")</P>
<P>S9 radioxerost*</P>
<P>S8 radioxerost*</P>
<P>S7 xerostomi*</P>
<P>S6 (MH "Xerostomia")</P>
<P>S5 S1 OR S2 OR S3 OR S4</P>
<P>S4 irradiat*</P>
<P>S3 radiat*</P>
<P>S2 radioth*</P>
<P>S1 (MH "Radiotherapy")</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-09-30 12:59:34 +0100" MODIFIED_BY="Anna Hobson" NO="2">
<TITLE MODIFIED="2015-05-17 16:14:00 +0100" MODIFIED_BY="[Empty name]">Additional outcome data</TITLE>
<APPENDIX_BODY MODIFIED="2015-09-30 12:59:34 +0100" MODIFIED_BY="Anna Hobson">
<TABLE COLS="3" ROWS="10">
<TR>
<TH COLSPAN="3">
<P>Additional outcome data</P>
</TH>
</TR>
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Primary outcomes</P>
</TH>
<TH>
<P>Secondary outcomes</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Davies-1994" TYPE="STUDY">Davies 1994</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Change in 100 mm VAS</P>
<P>
<B>Pilocarpine</B> - mean +22.5 mm</P>
<P>
<B>Saliva Orthana</B> - mean +15.2 mm</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Change in 100 mm VAS</P>
<P>
<B>Pilocarpine</B>
</P>
<P>dysphagia: mean +11 mm</P>
<P>dysgeusia: mean +18.4 mm</P>
<P>
<B>Saliva Orthana</B>
</P>
<P>dysphagia: mean +5.6 mm</P>
<P>dysgeusia: mean +1 mm</P>
<P/>
<P>
<B>Adverse effects:</B>
</P>
<P>
<B>Pilocarpine</B>
</P>
<P>nausea - 4/20 (20%)</P>
<P>sweating - 3/20 (15%)</P>
<P>lacrimation - 2/20 (10%)</P>
<P>headache - 1/20 (5%)</P>
<P>oral discomfort - 1/20 (5%)</P>
<P>GI colic - 1/20 (5%)</P>
<P>blurred vision - 1/20 (5%)</P>
<P>rhinorrhoea - 1/20 (5%)</P>
<P>urinary frequency - 1/20 (5%)</P>
<P>
<B>Saliva Orthana</B>
</P>
<P>headache - 2/20 (10%)</P>
<P>oral discomfort - 2/20 (10%)</P>
<P>nausea - 1/20 (5%)</P>
<P/>
<P>
<B>Withdrawals (see notes):</B>
</P>
<P>
<B>Pilocarpine</B> - 1 (adverse effects)</P>
<P>
<B>Saliva Orthana</B> - 1 (adverse effects)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Notes</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Original trial data could not be traced.</P>
<P>Data on efficacy relates to those participants who completed the study (17/20 participants).</P>
<P>No period/carry-over effect reported.</P>
<P>The improvement in xerostomia was not statistically significant.</P>
<P>The paper reports that 10/17 participants preferred the pilocarpine, 4/17 preferred the Saliva Orthana, and 3/17 had no preference; 8/17 participants wanted to continue with the pilocarpine, 3/17 wanted to continue with the Saliva Orthana, and 6/17 did not want to continue with either treatment after the trial. It is unclear what treatment 1 patient was taking when they were withdrawn from the study</P>
</TD>
</TR>
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Primary outcomes</P>
</TH>
<TH>
<P>Secondary outcomes</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Johnson-1993" TYPE="STUDY">Johnson 1993</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&gt; +25 mm change in 100 mm VAS</P>
<P>
<B>Pilocarpine 5 mg</B> - 32/63 (51%)</P>
<P>
<B>Pilocarpine 10 mg</B> - 24/51 (47%)</P>
<P>
<B>Placebo</B> - 15/59 (25%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&gt; +25 mm change in 100 mm VAS</P>
<P>
<B>Pilocarpine 5 mg</B>
</P>
<P>oral discomfort: 21/59 (36%)</P>
<P>speaking ability: 21/56 (38%)</P>
<P>&#8220;overall condition&#8221;: 37/69 (54%)</P>
<P>
<B>Pilocarpine 10 mg</B>
</P>
<P>oral discomfort: 18/45 (40%)</P>
<P>speaking ability: 17/47 (36%)</P>
<P>&#8220;overall condition&#8221;: 23/52 (44%)</P>
<P>
<B>Placebo</B>
</P>
<P>oral discomfort: 5/57 (9%)</P>
<P>speaking ability: 8/54 (15%)</P>
<P>&#8220;overall condition&#8221;: 15/62 (24%)</P>
<P/>
<P>Any increase in whole salivary flow rate after dose (at end of study)</P>
<P>
<B>Pilocarpine 5 mg</B> - 46/64 (72%)</P>
<P>
<B>Pilocarpine 10 mg</B> - 27/40 (68%)</P>
<P>
<B>Placebo</B> - 33/54 (61%)</P>
<P/>
<P>
<B>Adverse effects:</B>
</P>
<P>
<B>Pilocarpine 5 mg</B>
</P>
<P>sweating - 27/73 (37%)</P>
<P>headache - 11/73 (15%)</P>
<P>urinary frequency 10/73 (14%)</P>
<P>vasodilatation - 9/73 (12%)</P>
<P>dizziness - 7/73 (10%)</P>
<P>dyspepsia - 7/73 (10%)</P>
<P>nausea - 6/73 (8%)</P>
<P>asthenia - 6/73 (8%)</P>
<P>diarrhoea - 4/73 (5%)</P>
<P>rhinitis - 3/73 (4%)</P>
<P>chills - 1/73 (1%)</P>
<P>
<B>Pilocarpine 10 mg</B>
</P>
<P>sweating - 55/69 (80%)</P>
<P>chills - 16/69 (23%)</P>
<P>nausea - 15/69 (22%)</P>
<P>dizziness - 13/69 (19%)</P>
<P>rhinitis - 13/69 (19%)</P>
<P>vasodilatation - 12/69 (17%)</P>
<P>headache - 10/69 (14%)</P>
<P>urinary frequency - 10/69 (14%)</P>
<P>asthenia - 10/69 (14%)</P>
<P>diarrhoea - 8/69 (12%)</P>
<P>dyspepsia - 7/69 (10%)</P>
<P>
<B>Placebo</B>
</P>
<P>headache - 6/65 (9%)</P>
<P>urinary frequency - 6/65 (9%)</P>
<P>sweating - 5/65 (8%)</P>
<P>diarrhoea - 4/65 (6%)</P>
<P>rhinitis - 4/65 (6%)</P>
<P>vasodilatation - 3/65 (5%)</P>
<P>dyspepsia - 3/65 (5%)</P>
<P>nausea - 2/65 (3%)</P>
<P>dizziness - 1/65 (2%)</P>
<P>asthenia - 1/65 (2%)</P>
<P/>
<P>
<B>Withdrawals:</B>
</P>
<P>
<B>Pilocarpine 5 mg</B>
</P>
<P>8 (11%) - 4 adverse effects, 2 protocol deviation, 1 non-concordance, 1 personal reasons</P>
<P>
<B>Pilocarpine 10 mg</B>
</P>
<P>27 (39%) - 20 adverse effects, 3 personal reasons, 2 lack of effect, 1 protocol deviation, 1 &#8220;other&#8221;</P>
<P>
<B>Placebo</B>
</P>
<P>6 (9%) - 2 adverse effects, 2 lack of efficacy, 1 non-concordance, 1 personal reasons</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Notes</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Drug company declined to supply additional data.</P>
<P>The paper reports decrease in the use of saliva substitutes/other agents in 18/69 participants using pilocarpine 5 mg, 18/52 participants using pilocarpine 10 mg, and 5/62 participants using placebo.</P>
<P>The majority of participants responded within 4 weeks of the start of treatment, although some participants did not respond until 8 to 12 weeks</P>
</TD>
</TR>
<TR>
<TH VALIGN="BOTTOM">
<P>Study ID</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Primary outcomes</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Secondary outcomes</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-LeVeque-1993" TYPE="STUDY">LeVeque 1993</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&gt; +25 mm change in 100 mm VAS</P>
<P>
<B>Pilocarpine</B> - 28/66 (42%)</P>
<P>
<B>Placebo</B> - 21/77 (27%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&gt; +25 mm change in 100 mm VAS</P>
<P>
<B>Pilocarpine</B>
</P>
<P>oral discomfort: 15/58 (26%)</P>
<P>speaking ability: 25/59 (42%)</P>
<P>&#8220;overall condition&#8221;: 32/69 (46%)</P>
<P>
<B>Placebo</B>
</P>
<P>oral discomfort: 14/69 (20%)</P>
<P>speaking ability: 19/71 (27%)</P>
<P>&#8220;overall condition&#8221;: 20/77 (26%)</P>
<P/>
<P>Any increase in whole salivary flow rate after dose (at end of study)</P>
<P>
<B>Pilocarpine</B> - 32/46 (70%)</P>
<P>
<B>Placebo</B> - 22/46 (48%)</P>
<P/>
<P>
<B>Adverse effects:</B>
</P>
<P>
<B>Pilocarpine 5 mg</B>
</P>
<P>sweating - 14/68 (21%)</P>
<P>rhinitis - 4/68 (6%)</P>
<P>nausea - 3/68 (4%)</P>
<P>chills - 3/68 (4%)</P>
<P>urinary frequency - 2/68 (3%)</P>
<P>vasodilatation - 2/68 (3%)</P>
<P>headache - 2/68 (3%)</P>
<P>dizziness - 1/68 (1%)</P>
<P>asthenia - 1/68 (1%)</P>
<P>dyspepsia - 1/68 (1%)</P>
<P>diarrhoea - 1/68 (1%)</P>
<P>
<B>Pilocarpine 10 mg</B>
</P>
<P>sweating - 27/52 (52%)</P>
<P>urinary frequency - 5/52 (10%)</P>
<P>rhinitis - 4/52 (8%)</P>
<P>vasodilatation - 4/52 (8%)</P>
<P>nausea - 3/52 (6%)</P>
<P>chills - 2/52 (4%)</P>
<P>dizziness - 2/52 (4%)</P>
<P>asthenia - 2/52 (4%)</P>
<P>
<B>Placebo</B>
</P>
<P>sweating - 8/87 (9%)</P>
<P>rhinitis - 7/87 (8%)</P>
<P>headache - 6/87 (7%)</P>
<P>urinary frequency - 5/87 (6%)</P>
<P>dizziness - 5/87 (6%)</P>
<P>nausea - 4/87 (5%)</P>
<P>dyspepsia - 4/87 (5%)</P>
<P>asthenia - 3/87 (3%)</P>
<P>diarrhoea - 3/87 (3%)</P>
<P>vasodilatation - 1/87 (1%)</P>
<P>chills - 1/87 (1%)</P>
<P/>
<P>
<B>Withdrawals:</B>
</P>
<P>
<B>Pilocarpine</B> - 12 (16%) - 11 adverse effects, 1 personal reasons</P>
<P>
<B>Placebo </B>- 18 (21%) - 9 adverse effects, 3 lack of effect, 3 personal reasons, 1 protocol deviation, 1 non-concordance, 1 &#8220;other&#8221;</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Notes</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Drug company declined to supply additional trial data.</P>
<P>The participants did not respond to the 2.5 mg dose of pilocarpine. The paper reports decrease in use of saliva substitutes/other agents in 18/69 participants using pilocarpine and 10/77 participants using placebo. The paper reports that &#8220;adverse effects were generally mild&#8221;</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;TOTAL number of studies included in quantitative analysis- 3&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 studies included in previous version of review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 new studies included&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;82 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;82 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;104 records indentified through database searching (2005-July 2015)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;74 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;8 full-text articles excluded with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>